RxDoctor Payments Data

Elio Vento, MD

Internal Medicine · Elgin, ILNPI 1487717492

Payments from drug & device makers

$1,629in general payments, 2019–2025

Across 65 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$300
  • Johnson & Johnson$269
  • Pfizer$220
  • AbbVie$219
  • Lilly USA, LLC$168
  • AstraZeneca$148
  • plus $305 from 9 others

What the payments were for

  • Food & beverage$1,61399%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,629 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$380,145
Medicare patients
971
Services billed
4,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban627$283,063
JardianceEmpagliflozin185$150,816
XareltoRivaroxaban214$106,364
OzempicSemaglutide83$95,790
JanuviaSitagliptin Phosphate118$70,866
FarxigaDapagliflozin Propanediol62$39,565
XifaxanRifaximin12$36,960
MyrbetriqMirabegron119$36,789
EntrestoSacubitril/Valsartan63$29,626
GenotropinSomatropin34$22,954
Atorvastatin Calcium1,514$20,278
Potassium Chloride775$17,876
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog102$17,298
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$16,451
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr33$16,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Genotropin, Premarin$220$311,414691 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$13$172,101233 claims
Johnson & JohnsonXarelto$269$106,364214 claims
Novo NordiskOzempic$300$95,79083 claims
AstraZenecaFarxiga, Brilinta$148$45,52590 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$18$16,0011,293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →